Search for Clinical Trial Results

Sponsored By

Choroidal Neovascularization - 17 Studies Found

Status Study
Completed Study Name: Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Condition: Choroidal Neovascularization
Date: 2006-08-09
Interventions:
  • Drug: Ranibizumab 0.3 mg/0.05

Completed Study Name: Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
Condition: Choroidal Neovascularisation
Date: 2009-12-21
Interventions: Drug: ranibizumab 0.5mg
Recruiting Study Name: TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration
Condition: Choroidal Neovascularization
Date: 2005-11-29
Interventions: Procedure: Photodynamic therapy versus Transpupillary thermotherapy
Completed Study Name: Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
Condition: Myopic Choroidal Neovascularization
Date: 2008-11-24
Interventions: Drug: Injection Intravitreal injection of 1.25 mg bevacizumab
Withdrawn Study Name: Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Condition: Choroidal Neovascularization
Date: 2006-11-22
Interventions: Drug: Imatinib Mesylate /Ranibizumab
Completed Study Name: Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
Condition: Choroidal Neovascularization (CNV)
Date: 2013-04-23
Interventions:
  • Drug: Ranibizumab Ranibizumab

Completed Study Name: Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization
Condition: Subfoveal Choroidal Neovascularization
Date: 2006-12-01
Interventions:
  • Drug: intravitreal injection of ranibizumab
Completed Study Name: Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Condition: Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Date: 2013-08-12
Interventions:
  • Drug: Ranibizumab 0.5mg 0.5 mg
Completed Study Name: Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
Condition: Choroidal Neovascularization
Date: 2006-11-01
Interventions: Drug: ranibizumab 0.5mg intravitreal injection
Completed Study Name: Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Condition:
  • Choroidal Neovascularization
  • Myopia, Degenerative

Date: 2011-08-22
Interventions: Drug: Combretastatin A-4 Phosphate Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/-
Next >>>